Keeping Track: Regeneron Wins US FDA OK For Evkeeza, New Libtayo Uses; G1 Cosela Cleared
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker
You may also be interested in...
Finance Watch: Public Market Doldrums Have Not Sunk Private Company Funding Yet
ARCH closed a $3bn VC fund to end the month of June while in the same week six public biopharma firms said they are cutting jobs. Even so, some publicly traded companies have been able to launch sizeable offerings, including a $450m note sale by Cytokinetics and Xenon’s $250m follow-on.
First-In-Class Drugs Made Up More Than Half Of US FDA’s Novel Approvals Last Year
CDER hit a high mark with 27 first-in-class approvals in the 50 novel agents cleared in 2021.
Leo’s Tralokinumab Among 11 New Approval Hopefuls In EU
The developers of eleven new drugs could learn this week whether the European Medicines Agency will set them on course for pan-EU marketing approval.